The cervical cancer vaccine in Ireland: Well worth the wait
Keywords:
MedicineAbstract
Cervical cancer is the third most common cancer in women and results in approximately 300,000 deaths worldwide per annum. Research has un- covered that infection with particular types of the human papilloma virus (HPV) is the strongest independent risk factor for the development of cervical carcinoma. Due to this relationship, vaccines against the foremost carcinogenic strains of the virus were developed in hopes that they would prevent the subsequent development of malignancy. Two vaccines currently exist: the quadrivalent vaccine, Gardasil and the bivalent vaccine, Cervarix. Both vaccines target the two Human Papillomavirus strains that are most commonly associated with the development of cervical cancer, types 16 and 18. The Gardasil vaccine also targets Human Papillomavirus types 6 and 11, which are commonly associated with genital warts. Five- year follow-up studies have shown both vaccines to be over 90% efficacious. There is, however, a lack of long-term data on both vaccines and more research is necessary to further evaluate their long-term outcomes on the prevention of malignancy. Currently, the major protection offered to women in Ireland against cervical cancer is that of secondary prevention via regular screening with the papanicolaou smear. A vaccine campaign is due to commence later this year, with the introduction date currently set as September 2010. It is expected that immunisation against the Human Papillomavirus in combination with regular papanicolaou smear screening will result in a reduction in the incidence of cervical cancer in Ireland. In this review, the link between cervical cancer and the Human Papillomavirus will be discussed in addition to providing support for the introduction of the Human Papillomavirus vaccines into the Irish immunisation schedule.
References
2 National Cancer Registry of Ireland [Online]. 1991 September [Cited 2010 March 4]; Available from:
URL: http://ncri.ie/ncri/index.shtml
3 American Caner Society [Online]. 2008 November [Cited 2010 March 4]; Available from: URL: http:// www.cancer.org/docroot/home/index.asp?level=0
4 Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189: 1-3.
5 Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; et al. Robbins Basic Pathology.8th ed. Saunders:Elsevier;2007.
6 Health Information and Quality Authority[Online]. 2007 May [Cited 2010 March 4]; Available from: URL: http://www.hiqa.ie
7 Keegan H, Ryan F, Malkin A, et al. Human papillomavirus prevalence and
genotypes in an opportunistically screened Irish female population. Br J Biomed Sci 2007; 64:18-22.
8 Mc Inerney J, Pilkington L, Keegan H, Ring M, Bolger N, Casey M, et al. Prevalence and genotype distribution of Human Papilloma Virus in the Irish Cervical Screening Population. Eurogin 2008; Joining forces for cervical cancer prevention, Nice, France.
9 CervicalCheck[online].2008 September [Cited 2010 March 4]; Available from: URL:http://www. cervicalcheck.ie/_fileupload/File/Guide%20for%20 Smeartakers_Jan_09/Section%203%20Cervical%20 Cancer%20&%20Screening.pdf
10 Archana Monie, Chien-Fu Hung,Richard Roden,
TM
and T-C Wu. Cervarix : a vaccine for the prevention
of HPV 16, 18-associated cervical cancer. Biologics. March 2008; 2(1): 97–105.
11 Münger, Howley, PM. Human papillomavirus immortalization and transformation functions. Virus research. 2002; 89 (2): 213–28.
12 Pagliusi SR and Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578.
13 Hakama, M., Miller, A.B., Day, N.E. Screening for Cancer of the Uterine Cervix. IARC Press Lyon: 1986. 14 Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dubin G et al: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Epub. 2006; 24(33-34):5937-49.
15 Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, et al; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human Papillomavirus type 16 and 18 L1 virus- like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40(6):564-71.
16 Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE,Marchant CD et al: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov;118(5):2135-45.
17 US Food and Drug Administration [Online]. 2006 June [Cited 2010 Feb28]; Available from: URL:http:// www.fda.gov
18 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
19 Paavonen, J., Jenkins, D., Bosch, F.X., et al. Efficacy of a Prophylactic Adjuvanted Bivalent L1Virus- like-particle Vaccine against Infection with Human Papillomavirus Types 16 & 18 in Young Women: An Interim Analysis of a Phase III Double-blind, Randomised Controlled trial. Lancet.2007; 369:2161. 20 Gall SA, Teixeira J, Wheeler CM, et al. Substantial impact on pre-cancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV- 16/18 L1 VLP AS04 candidate vaccine. AACR Annual Meeting; Los Angeles, CA.2007; 4900.
21 Muñoz, N., Bosch, F.X., Chichareon, S., Eluf-Neto,J., Ngelangel, et al. A multinational case-control study on the risk of cervical cancer linked to 25 HPV types: which are the high risk types? International Papillmavirus Conference – Program and Abstracts Book.2000.
22 Kyrgiou, M. & Mahmood I. S.: The Risks and Benefits of HPV Vaccination. Obstetrics, Gynaecology &Reproductive Medicine.2009; 19:26-28.
23 Roden RB, Ling M, Wu TC. “Vaccination to prevent and treat cervical cancer”. Human pathology. 2004; 35 (8): 971–82
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
